Cromolyn

Cromolyn (Cromoglycate) is an orally active GSK-3β inhibitor with an IC₅₀ of 2.0 μM. Cromolyn is also a mast cell stabilizer that can inhibit the release of mediators from mast cells, regulate reflex bronchoconstriction, and reduce non-specific bronchial hyperreactivity, and Cromolyn can be used in the research of bronchial asthma. In addition, Cromolyn has multiple activities such as anti-inflammatory, anti-allergic, anti-histamine, anti-cancer, and neuroprotective effects^{[1][2][3][4][5]}. In Vitro:Cromolyn (0-100 μM; 3-10 min) can inhibit IgE- and antigen-induced degranulation and PGD₂ synthesis in rat peritoneal mast cells^[1].
Cromolyn (0-100 μM; 0-72 h) can block S100P-promoted cell proliferation, invasion, and increased NF-κB activity in Panc-1 cells^[2]. In Vivo:Cromolyn (10 mg/kg; intravenous injection; single dose) can significantly inhibit mast cell activation in IgE-dependent PCA by reducing Evans blue extravasation and completely inhibit antigen-induced plasma histamine increase in PSA in rats^[1].
Cromolyn (5 mg/kg; intraperitoneal injection; 5 weeks) has anti-tumor activity in a mouse model of pancreatic cancer^[2].
Cromolyn (6.3 mg/kg; intraperitoneal injection; 5 times a week; from postnatal day 60 until euthanasia) has an ameliorative effect in a model of amyotrophic lateral sclerosis^[3].
Cromolyn (1-3.15 mg/kg; intraperitoneal injection; 3 times a week; 12 weeks) has a neuroprotective effect in a mouse model of Alzheimer's disease^[4].
Cromolyn (1.43-5.72 mg/kg; intraperitoneal injection; 1 month) has a hypoglycemic effect in mice^[5].